KineMed and Organon Enter Collaboration to Discover New Therapeutic Applications for Multiple Drug Candidates
KineMed, Inc., a pathway-based drug discovery and development company, and Organon announced that they have signed an agreement to discover new applications for multiple drug candidates.
Under the terms of the agreement, KineMed will apply its proprietary technologies (AquaTag(TM) and KineMarker(TM)) to find alternative applications for discontinued compounds formerly in Organon's clinical-stage pipeline. Once therapeutic utility is established for a selected drug candidate, KineMed and Organon will jointly determine a development and commercialization path, including a potential joint development and commercialization program.
David Nicholson, Executive Vice President of Global Research & Development at Organon, stated, "We at Organon are dedicated to maximize the potential of R&D compounds. KineMed's ability to measure the outputs of complex pathways in in vivo studies may lead to the discovery of new indications and as such holds great promise."
"Our focus at KineMed is to maximize the value of drug compounds, applying our technology to discover indications that would have otherwise gone undetected and thereby enabling new avenues for drug development and commercialization," said David Fineman, President and CEO of KineMed. "We are pleased to announce the collaboration with Organon, which is a significant demonstration of our ability to forge partnerships with healthcare organizations that are leading the innovation of new therapies worldwide."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.